US EditionPublished • loading... • Updated
Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer
The Phase 1/2 trial evaluates PRV131's safety and efficacy as a neoadjuvant therapy to shrink oral tumors and improve surgical outcomes, with over 80% tumor reduction in preclinical studies.
- Dec. 10, 2025, Privo Technologies, Inc. dosed the first patient in Arm 3 of the Phase 1/2 CLN-004 study testing PRV131 for T1–T3 oral squamous cell carcinoma.
- Built on Privo's PRV Platform, PRV131 is designed to shrink tumors directly at the site to preserve oral structures and deliver high cisplatin concentrations to improve surgical outcomes.
- The preclinical results underpinning PRV131 include companion animal studies in dogs showing over 80% tumor reduction without systemic toxicity and expanding Privo's PRV portfolio toward intratumoral delivery for oral malignancies.
- The trial has opened at its first clinical site, where the inaugural patient received treatment, marking a key milestone in development of novel locoregional therapies for head and neck cancer and expanding the PRV program beyond patches toward intratumoral cisplatin for oral cavity malignancies.
- Looking beyond the milestone, Privo Technologies, Inc. described this as a key step to transform local cancer treatment with local, nanoengineered chemotherapy and said Dr. Manijeh Goldberg, PhD, Founder and CEO, "We are incredibly pleased to begin dosing patients with PRV131 in this first-in-human study.
Insights by Ground AI
33 Articles
33 Articles
Coverage Details
Total News Sources33
Leaning Left3Leaning Right1Center9Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 23%
C 69%
Factuality
To view factuality data please Upgrade to Premium
